Good H1 for Johnson Matthey

Sales for Johnson Matthey's fine chemicals division rose 8% to £122m in H1 and for its APIs manufacturing businesses, Macfarlan Smith and Pharmaceutical Materials and Services, sales rose 5% to £88m. The company said that growth at Macfarlan Smith was led by sales of bulk opiates and other controlled APIs and Pharmaceutical Materials and Services' strong performance was mainly due to continued good growth in sales of specialist opiates, amphetamines and platinum anticancer APIs.
Earlier in November, Johnson Matthey acquired a dedicated APIs manufacturing facility in Conshohocken, PA, together with some ongoing businesses. The company said the facility will provide additional capacity and greater flexibility to continue to grow its North American controlled substances business.
Johnson Matthey